Simplified Chinese
Tender Notice for BIM Services for the Minhai Biotechnology New Vaccine International Industrial Base Construction Project
Release date:
2020-08-12
Author:
Source:
Abstract
I. Project Name: Minhai Biotechnology’s New‑Generation Vaccine International Industrial Base Construction Project
II. Project Overview:
The Minhai Biologics International Vaccine Industrial Base Project, invested in and constructed by Beijing Minhai Biotechnology Co., Ltd., is located on parcels 0503-039, 040, 043, and 044 within the Daxing Biomedical Industry Base. The project’s boundaries are as follows: to the north, Simiao Road; to the south, the planned land‑use boundary (municipal green space); to the west, Xiangrui Avenue; and to the east, Tianfu Avenue. The project is primarily dedicated to the research, development, and production of human vaccines.
Construction scale: Total land area of 90,013.218 m² 2 , with a total floor area of 187,684.83 m² 2 (Of which, the above-ground floor area is 130,410.84 m²) 2 , underground floor area 57,273.99 m² 2 ). The building has a height of 33.3 meters, with one basement level and seven above-ground floors. The basement floor-to-floor height is 6 meters, while the above-ground floors range from 3.8 to 7.9 meters in height. The site coverage ratio is 15%, the floor area ratio is 1.5, and the building density is 40%.
Planned commencement and completion dates: September 2020 – March 2023.
Quality Standards: Meet national and industry‑approved standards.
III. Scope of the Tender:
The scope of this tender covers BIM services for the Minhai Biotechnology New‑Generation Vaccine International Industrial Base Project, with the primary scope encompassing BIM detailed design and related services for the construction drawings of Basement No. 12. The final scope and requirements shall be governed by the tender documents and the contract.
IV. Registration Instructions:
1. Bidding‑eligible entities must submit the following documents in quadruplicate: the business license of the legal entity, qualification certificates, a certificate of the legal representative or a letter of authorization from the legal representative, and copies of identification documents. All copies must bear the official seal of the submitting entity, and the company’s registered capital must be clearly indicated.
2. Bidding entities must possess a qualified professional team and have previously delivered end-to-end BIM services for projects in the relevant industry.
3. Registration requires the provision of a contact person and contact information from the submitting organization. The contact person must be the project leader or an designated business liaison, and a 12-month social security certificate must be submitted.
4. The tendering entity will review the qualification documents submitted by registered entities, giving priority to those with relevant project experience. Selected entities will undergo further communication and on-site evaluation, and the tender documents will be issued only to the shortlisted candidates.
5. This tender does not accept consortium bids.
6. Beijing Minhai Biotechnology Co., Ltd. was established in 2004 and is a wholly owned subsidiary of Shenzhen Kangtai Biological Products Co., Ltd. (a publicly listed company). For more information, please visit the company’s website.
V. Registration Address: Beijing Minhai Biotechnology Co., Ltd. (No. 35, Simiao Road, Bio‑Pharmaceutical Industry Base, Daxing District, Beijing).
Contact persons: Mr. Ma and Mr. Hao, New Engineering Project Department; contact numbers: 010-57864910, 010-57864916.
Electronic materials have been sent to the email address: mhzb @biominhai.com
VI. Registration Deadline: 5:30 p.m., August 25, 2020.
Hereby announced!
Beijing Minhai Biotechnology Co., Ltd.
August 11, 2020
Keywords:
Recommended Reading
Batch Release Status of the Company’s Products in 2026
2026-07-23
2026-07-15
2026-07-09